Female Founder
Serial EntrepreneurAbout
RNA AI Platform for next-generation cures. Provides OneRNA® platform-as-a-service for analyzing RNA to individualize cancer treatment, design clinical studies, and translate RNA data to RNA therapeutics. Achieves 100% diagnostic yield by matching all patients to FDA-approved drugs.
Traction & Metrics
Financial
$4.5M
ARR
Fundraising
$1.7M
Previous Round
Products
OneRNA® Platform
AI-enabled RNA sequencing platform that analyzes 20,000 RNAs to individualize cancer treatment with 100% diagnostic yield. Provides OneRNA® chemistry for RNA stabilization in clinical samples, OneRNA® database of normal RNA expression, and drug database linking RNA patterns to FDA-approved treatments. Enables tissue and disease agnostic analysis, clinical study design, and translation to RNA therapeutics. CLIA certified with existing payor codes at $3,000/test.
Click to read more
OneRNA® reagent kit
Proprietary reagent kit for RNA sample preparation and stabilization in clinical samples. Enables quantitative RNA sequencing from FFPE tissue, blood, and other clinical sample types in which RNA is otherwise destroyed. Designed for implementation at hospitals with API integration to EMR systems.
Click to read more
OneRNA® Cloud
Cloud-based AI platform for RNA data analysis across cancer, infectious disease, autoimmune, health, and CNS indications. Provides algorithms for treatment selection, drug repurposing, clinical study design, and RNA therapeutic development.
Click to read more
Circulating Tumor Cell Assay
Platform for testing individualized RNA therapeutics and CAR-T in live patient cells before treatment. Enables collection of whole blood; enrichment of Circulating Tumor Cells (CTCs), B, T, and other lymphocytes; RNA analysis; functional testing; development of individualized RNA therapeutics; and pre-treatment validation in patient cells.
Click to read more
RNA Therapeutic Manufacturing
Rapid manufacturing platform for truly individualized RNA therapeutics. Reduces manufacturing time from 9 weeks to 1 week. Translates RNA code to therapeutic interventions including drug repurposing, combination with individualized RNA therapeutics, and novel miRNA-based treatments for conditions like Peripheral Artery Disease.
Click to read more